Pelthos Therapeutics Inc. (PTHS) – What Are Brokerages Thinking About This Stock?

Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) has received an average rating of “Moderate Buy” from the seven brokerages that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation and six have issued a buy recommendation on the company. The average 12 month target price among analysts that have covered the stock in the last year is $52.83.

PTHS has been the subject of several research reports. Lake Street Capital dropped their target price on Pelthos Therapeutics from $50.00 to $40.00 and set a “buy” rating for the company in a research report on Monday, October 12th. Oppenheimer reduced their price target on shares of Pelthos Therapeutics from $66.00 to $64.00 and set an “outperform” rating on the stock in a research report on Friday, August 14th. Finally, Zacks Research cut shares of Pelthos Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Wednesday, October 7th.

Institutional Investors Weigh In On Pelthos Therapeutics

A hedge fund recently raised its position in Pelthos Therapeutics stock. Pale Fire Capital SE grew its holdings in Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) by 59.5% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 12,919 shares of the company’s stock after acquiring an additional 4,819 shares during the period. Pale Fire Capital SE owned about 0.38% of Pelthos Therapeutics worth $271,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 77.96% of the company’s stock.

Pelthos Therapeutics Stock Up 4.8%

Shares of NYSEAMERICAN PTHS opened at $19.59 on Friday. The company has a quick ratio of 1.31, a current ratio of 1.98 and a debt-to-equity ratio of 3.40. Pelthos Therapeutics has a twelve month low of $18.19 and a twelve month high of $37.50. The stock has a fifty day simple moving average of $22.72 and a 200-day simple moving average of $25.07.

Pelthos Therapeutics (NYSEAMERICAN:PTHS) last posted its earnings results on Thursday, August 13th. The company reported ($6.62) earnings per share (EPS) for the quarter. Pelthos Therapeutics had a negative return on equity of 204.71% and a negative net margin of 165.24%. The firm had revenue of $15.60 million for the quarter. As a group, sell-side analysts expect that Pelthos Therapeutics will post -15.22 earnings per share for the current year.

Pelthos Therapeutics Company Profile

Pelthos Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for pain management. The company’s work is centered on addressing unmet needs in the treatment of acute and chronic pain, including the development of potential alternatives to traditional opioid-based medicines.

Pelthos Therapeutics is advancing investigational drug candidates through preclinical and clinical development. As with other clinical-stage biotechnology companies, its products remain subject to testing and regulatory review, and there is no assurance that any candidate will receive approval or become commercially available.

Publicly available information about the company’s specific product pipeline, operating history, geographic reach and leadership is limited.